Press release
GM2 Gangliosidosis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight
GM2 Gangliosidosis Pipeline
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis.
"GM2 Gangliosidosis Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the GM2 Gangliosidosis Market.
The GM2 Gangliosidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
To know more about the GM2 Gangliosidosis Pipeline Report, click here: https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's GM2 Gangliosidosis Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging GM2 Gangliosidosis Drugs Under Different Phases of Clinical Development Include:
• Venglustat: Sanofi
• AXO-AAV-GM2: Sio Gene Therapies
And Many Others
Further GM2 Gangliosidosis product details are provided in the report. Download the GM2 Gangliosidosis pipeline report to learn more about the emerging GM2 Gangliosidosis therapies at: https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
GM2 Gangliosidosis Pipeline Analysis
The GM2 Gangliosidosis report provides insights into:
The report provides detailed insights about companies that are developing therapies for the treatment of GM2 Gangliosidosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the GM2 Gangliosidosis Treatment.
GM2 Gangliosidosis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
GM2 Gangliosidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the GM2 Gangliosidosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF Report to know more about GM2 Gangliosidosis Pipeline Assessment- https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key companies in the GM2 Gangliosidosis Therapeutics Market:
Some of the GM2 Gangliosidosis companies working in the market are Sanofi, Sio Gene Therapies, IntraBio Inc., Taysha Gene Therapies, JCR Pharmaceuticals, Azafaros B.V, Allievex Corp., Recursion, Polaryx and Others.
Request for Sample PDF Report for detailed GM2 Gangliosidosis clinical trial assessment- https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. GM2 Gangliosidosis Current Treatment Patterns
4. GM2 Gangliosidosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. GM2 Gangliosidosis Late Stage Products (Phase-III)
7. GM2 Gangliosidosis Mid-Stage Products (Phase-II)
8. GM2 Gangliosidosis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. GM2 Gangliosidosis Discontinued Products
13. GM2 Gangliosidosis Product Profiles
14. Key Companies in the GM2 Gangliosidosis Market
15. Key Products in the GM2 Gangliosidosis Therapeutics Segment
16. Dormant and Discontinued Products
17. GM2 Gangliosidosis Unmet Needs
18. GM2 Gangliosidosis Future Perspectives
19. GM2 Gangliosidosis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about the GM2 Gangliosidosis drugs and therapies- https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• T-Cell-Prolymphocytic Leukemia Market: https://www.delveinsight.com/report-store/t-cell-prolymphocytic-leukemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Hepatic Encephalopathy Epidemiology Forecast: https://www.delveinsight.com/report-store/hepatic-encephalopathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Age Related Vision Dysfunction Market: https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM2 Gangliosidosis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight here
News-ID: 2722432 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for GM2
GM2 Gangliosidosis Market Outlook, Trends, Therapies and Growth Forecast
GM2 gangliosidosis is a group of rare, inherited lysosomal storage disorders caused by mutations in the HEXA, HEXB, or GM2A genes, leading to defective β-hexosaminidase enzyme activity. This results in the accumulation of GM2 ganglioside in neurons, causing progressive neurodegeneration. The most common forms include Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913
Although rare, GM2 gangliosidosis represents a critical unmet need…
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approv …
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and…
GM2 Gangliosidosis Market Set to Advance Through 2034, Fueled by Gene Therapy In …
GM2 Gangliosidosis refers to a group of rare, inherited lysosomal storage disorders-including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency-caused by mutations that impair the breakdown of GM2 gangliosides in nerve cells. These disorders are characterized by progressive neurodegeneration, muscle weakness, motor impairment, seizures, and early mortality, especially in infantile-onset forms. The most common types, Tay-Sachs and Sandhoff disease, result from mutations in the HEXA and HEXB genes, respectively.
DelveInsight's report,…
GM2 Gangliosidosis Pipeline Overview: 8+ Innovative Therapies Driving Hope in Ra …
The therapeutic landscape for GM2 gangliosidosis-an ultra-rare, inherited lysosomal storage disorder encompassing Tay-Sachs and Sandhoff diseases-is witnessing growing innovation, with the pipeline evolving toward more disease-modifying and potentially curative therapies. GM2 gangliosidosis is caused by mutations affecting β-hexosaminidase A and/or B enzymes, resulting in the toxic accumulation of GM2 gangliosides in neurons, which leads to progressive neurodegeneration. Despite the severity of this disease, current management remains largely supportive, highlighting an…
GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the F …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
GM2 Gangliosidosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the GM2 Gangliosidosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"GM2 Gangliosidosis Pipeline Insight, 2023" report…
